-
of theranostic radioligands targeting tumor-associated proteases. Project overview: The Radiopharmacy group has extensive expertise in the development of radiolabeled ligands for proteases implicated in human
-
research activities within the Radiopharmacy (CREANT) department and the Molecular Imaging Center Antwerp (MICA), focusing on the preclinical evaluation of theranostic radioligands targeting tumor
Searches related to target tracking
Enter an email to receive alerts for target-tracking positions